At the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin, Team Glooko had the exciting opportunity to meet new and old friends on the tradeshow floor and offer live demonstrations of the innovative Glooko and Glooko XT connected care platforms at our stand.

And the conference was all about our partnerships with leading global diabetes companies.

We hosted Dexcom, Novo Nordisk and Tandem in our stand to demonstrate how the Glooko platform works with their products for people living with diabetes and their care teams. We also joined these three industry partners in their stands to demonstrate how the Glooko connected care platform works with their digital health innovations and devices.

We announced our new partnership with Sanofi, which gives people with diabetes more choices in customizing their diabetes management by integrating the SoloSmart® cap for SoloStar® insulin pens with the Glooko connected care platform. This new integration will help improve insulin management and tracking, while supporting insulin dosing data.

While we already support an extensive and growing list of diabetes and health monitoring devices, Team Glooko met with over 45 of our partners to discuss how to bring more digital health solutions to healthcare providers.

Our poster presentation, “Remote Patient Monitoring and Glycemic Control Trends During the COVID-19 Pandemic,” highlighted the effectiveness of our remote care platform’s capabilities when healthcare delivery needed to rapidly shift due to stay-at-home orders, but clinicians needed to remain engaged and provide care to their patients with diabetes.

We were also a proud sponsor of the diaTribe Foundation and ATTD’s panel discussion, “Solvable Problems in Diabetes,” with leading experts around continuous glucose monitoring, time in range and associated therapeutic and data-driven interventions for people living with diabetes.

After an action-packed few days, our team is already looking forward to showcasing our latest innovations next year at ATTD 2024 in Florence.

MKT-0429 01

At Glooko, we improve the health outcomes of people with diabetes and related chronic conditions through our personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and healthcare providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials.

Through multiple clinical studies conducted, we’ve observed immediate and sustained improvements across multiple glycemic outcomes following remote patient monitoring (RPM). These findings show that RPM provides multiple clinical benefits and improved outcomes for people with diabetes.

Some of the highlights of our real-world data studies include:

• Delivering Improved and Sustained Glycemic Control^1,2,3

• Use of the Glooko Mobile App Improving Glycemic Outcomes in 2 Months⁴

• Declining Patient Outcomes  6-8 Weeks After Stopping Using Glooko⁵

Download the infographic (PDF) below for findings from our studies.

1. Sheng T et al. Glycemic Improvements Following Mobile-Enabled Remote Patient Monitoring: A Randomized Control Study, ADA Scientific Sessions, June 2020. 2. Clements M, Duffee J and McCarther D. Remote patient monitoring for adults with type 2 diabetes. ADCES Research Sessions, August, 2020. 3. Sheng T, Parks L and Clements M. Remote patient monitoring in the real world: Immediate and long-term improvements in glycemic control. American Association of Diabetes Educators (AADE) Annual Meeting, Houston TX. August, 2019. 4. Offringa R et al. Digital diabetes management application improves glycemic outcomes in people with type 1 and type 2 diabetes. Journal of diabetes science and technology, 12(3), 701-708. 2018. 5. Sheng T et al. Mobile-Enabled Food Logging is Associated with Improved Glycemic Management in the Real World. Diabetes Technology Meeting (DTM), 2019. 6. Abad R et al. Use of mobile-enabled reminders feature is associated with improved behavioral and glycemic outcomes in the real world. American Diabetes Association (ADA), Scientific Sessions, 2019. 7. Babikian S et al. Deteriorating Glucose Control in Patients with Diabetes after Disengagement from a Mobile Health App. Diabetes Technology Meeting, Poster, 2020.

MKT-0084 01

Glooko is excited to share that our digital health platform for people with diabetes and related chronic conditions is compatible in the United States with Insulet Corporation’s Omnipod® 5 Automated Insulin Delivery (AID) System.

The automated insulin delivery system, which is composed of the Omnipod 5 App, the Pod and has Dexcom® G6 Continuous Glucose Monitor (CGM) System integration, received FDA clearance for use by individuals ages 2 and older with type 1 diabetes in 2022.

As the first tubeless AID system with smartphone control* in the U.S., Omnipod 5 integrates with the Dexcom G6 CGM System to automatically adjust insulin, help protect against highs and lows in glucose levels**, and simplify life for people with diabetes. The system’s innovative Pod uses SmartAdjust™ technology that continuously and automatically regulates insulin delivery based on a patient’s customized Target Glucose.

“With the many benefits provided by the Omnipod 5, we’re thrilled it’s compatible and available to Glooko users in the U.S.,” said David Conn, Glooko’s Executive Vice President of Partnerships and Alliances. “Our partnership with Insulet allowed us to be compatible from launch with this innovative new AID system designed for people looking to better manage their diabetes.”

Through our integration with Insulet, patients using the Omnipod 5 can connect their system to Glooko and upload their data from home via a cloud connection, expediting the time spent with healthcare providers. Healthcare providers can review the data uploaded and view standardized, comprehensive reports in the Glooko dashboard to help gain insights and make decisions to optimize care.

“The team at Insulet appreciates the support Glooko provided to make the launch of the Omnipod 5 possible and successful,” said Dr. Trang Ly, MBBS, FRACP, Ph.D., Senior Vice President and Medical Director, Insulet. “This System has been life-changing for so many people living with type I diabetes and we look forward to continuing to see its impact.”

Along with the Omnipod 5, the Glooko platform is also compatible with Insulet Corporation’s Omnipod DASH®.

At Glooko, we’re continuously increasing the number of devices that are compatible with our digital health platform, and over 3 million users around the globe have benefited in managing their health with our tools. We’re currently compatible with a majority of global diabetes and health monitoring devices on the market, which gives patients and their healthcare providers flexibility in managing their diabetes and related chronic conditions.

*For a list of compatible smartphone devices visit omnipod.com/compatibility

**Study in 240 people with T1D aged 6 – 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021).

Study in 80 people with T1D aged 2 – 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Median time with low blood glucose from CGM: standard therapy = 3.43% vs. 2.46%. Sherr JL, et al. Diabetes Care (2022).

MKT-0358 01

​​Food is a critical component in the management of diabetes.

​​People with diabetes can use the Glooko mobile app, available in the App Store and Google Play Store, to easily log their food intake and keep a historical account of how food affects their chronic condition.

The data from daily meals can be viewed alongside data from compatible diabetes and health monitoring devices, medications and insulin to reveal trends and patterns to better understand what is affecting a person’s diabetes

Tracking food consumption in our digital health app can be handled in multiple different ways, including by searching the food database, using voice capture or scanning a barcode.

• Database Search: Manually search for a generic or branded food item in the Glooko mobile app by typing in its name to track it. Learn how to use this feature…

• Voice Capture: Speak the name of the food item that should be added to the Glooko mobile app’s food tracker. Explore how to use this unique functionality that is not available in other leading food tracking apps…

• Barcode Scanner: Use the camera of a smartphone to scan the barcode of a food item to track it in the Glooko mobile app. See how to take advantage of this feature…

The Glooko mobile app simplifies tracking food consumption while allowing users to explore nutrition facts, including carbohydrates, calories, fats and proteins.

Frequent users of the food tracker can also create personalized custom food entries of their favorite meals, so they don’t need to re-add portions multiple times.

“The food tracker feature in our mobile app allows users to see how the food they’re consuming each day may affect their diabetes,” said Glooko Chief Product Officer Ed Marshall. “Being able to see all the data in one place gives users the ability to understand how they’re doing and make informed decisions about their health.”

The Glooko mobile app and its food tracker feature is also constantly evolving to meet the needs of our global users.

To better support users in the U.K., France, Germany and Spain last year, we added unique regional food items that are searchable in British English, French, German and Spanish to our connected care app.

For handy ways on how to use the food tracker, follow along with healthy eating and living tips from Glooko’s resident dietitian, Bridget Wood, RD, LD, CDCES.

MKT-0417 01

​​Season’s Greetings!

​​As we reflect on the past year, I’d like to take a moment to sincerely thank you, our customers, partners, friends and families for your continued partnership and support. While changing external market dynamics continued to present new challenges and new opportunities – what did not change was our commitment to our mission. As we look ahead to 2023 we are excited to increase our impact and to take our solutions to the next level, pushing the envelope of digital health to deliver the strongest positive patient outcomes for people with chronic conditions. We have many things to be thankful for, and several exciting new initiatives to share with you in 2023.

​​Wishing you a very happy & healthy holiday, and we look forward to our continued partnership in the new year.

​​Warmest holiday greetings,

​​Russ Johannesson
Chief Executive Officer
Glooko

Glooko, a leading provider of intelligent, connected care solutions and remote patient monitoring (RPM) for people with diabetes and related chronic conditions, presented positive data from two recent studies on remote patient monitoring at the 2022 IDF World Diabetes Congress.

The first study presented by Team Glooko at the Congress, Cost and Outcomes of a Diabetes Remote Patient Monitoring System: A Simulation Analysis, was the company’s inaugural study using a health economics and outcomes research (HEOR) simulation model. In a randomized controlled trial of RPM and digital therapeutics (DTx), the intervention resulted in significantly improved HbA1c in patients with type 2 diabetes (T2D). Incorporating these results into a microsimulation model of longer-term complications, mortality and costs demonstrated the potential for RPM and DTx to elicit health gains and cost savings among people with diabetes.

The second study presented by Team Glooko, The Impact of Remote Patient Monitoring on Glycated Hemoglobin for Type 2 Diabetes: A Randomized Controlled Trial, demonstrated that a comprehensive 24-week RPM diabetes management program was more effective in improving HbA1c compared to usual care for adults with T2D.

These studies further showcase the clinical and economic benefits of the Glooko platform, which is sold to healthcare providers globally, and available for free as a mobile app to patients.

Team Glooko will continue to highlight the benefits of our connected care platform for diabetes and related chronic conditions at industry events in 2023.

MKT-0413 01

In honor of American Diabetes Month, we’re sharing stories of Team Glooko members who are living with diabetes or helping a family member who is impacted by the chronic condition.

On September 11, 2001, Phil Krieg, the global head of customer support and supply chain for Glooko, was diagnosed with type 1 diabetes.

While he’s only been at our connected care company for two years, he had always wanted to work at Glooko and was passionate about joining to further our mission since he’s been a long-time user of our app.

In his role, he works directly with people with diabetes and in many situations, the parents of children with diabetes, to help solve their issues. In these moments, it can be an especially scary time for parents.

“Empathy is key in my position,” said Phil. “I work closely with the users I’m supporting to work through any problems they’re facing as quickly and efficiently as possible.”

Leading the support team from California, he’s able to easily collect and share feedback from customers on the design of Glooko with the product development team, who is always willing to take new ideas and work them into fruition to further enhance the connected care solution.

And as one of the many people on Team Glooko living with diabetes who uses the mobile app on a daily basis, his mission-driven nature goes into the product design as well.

“I’m always looking for ways to improve our app and make it better for users, like myself,” said Phil.

Hear his story.

MKT-0407 03

In honor of American Diabetes Month, we’re sharing stories of Team Glooko members who are living with diabetes or helping a family member who is impacted by the chronic condition.

As a senior account manager at Glooko for the past 2.5 years, Patrick Watkins has helped hospital systems, healthcare providers and clinics maximize their functionality and take full advantage of what our digital health platform has to offer their patients with diabetes and related chronic conditions.

While Patrick himself isn’t living with diabetes, his daughter, Nuala, has been living with type 1 diabetes for over six years. Through the use of a closed loop system, the Glooko app and telehealth appointments, Patrick and his wife keep Nuala safe and healthy like any other child.

The duo, who act as JDRF ambassadors, are also dedicated to ensuring that other families know that their child, newly diagnosed with diabetes, will lead a healthy life and acclimate to living with the condition.

In Patrick’s role at our connected care company, he’s able to understand what his customers are faced with from both the patient and caregiver perspective due to his experiences at home. He’s also able to synthesize the various needs of providers, people with diabetes and caregivers to our product development team and ensure the best experience for all users of our app and platform.

“I really appreciate working at Glooko and being among so many people with diabetes,” said Patrick. “It’s a special place since so many people have the insights from using the app in their daily lives, so they’re constantly able to help build an even better product.”

Listen to his story.

MKT-0407 02

In honor of American Diabetes Month, we’re sharing stories of Team Glooko members who are living with diabetes or helping a family member who is impacted by the chronic condition.

Hadley Horton, a partner manager at Glooko, was diagnosed with type 1 diabetes in November of 2009.

When she’s not staying active to keep her blood sugar stabilized, she acts as an advocate for people with diabetes. She believes those with diabetes understand and are aware what it means to live with the condition best. In the past, she’s mentored youth with diabetes and their peers to remind them they’ll lead a normal life just like she has.

Based in Denver, Colorado, her role at our connected care company allows her to collaborate with teams across Glooko and our partner, Insulet, on how to expand and improve our digital health platform.

“In order to have a successful partnership, you need to work with everyone from product developers to patients,” said Hadley. “My role has given me a new perspective into the digital therapeutics space, as well as understanding of the broader diabetes industry.”

With her knowledge from working alongside partner companies, living with diabetes and using the Omnipod 5 in her daily life, she’s able to lend valuable insights into the continuous development of the Glooko app to enhance our product for users around the world.

Listen to her story.

MKT-0407 01

Recently, Glooko exhibited at ADCES22, the premier annual conference from the Association of Diabetes Care & Education Specialists covering all things diabetes care, education and technology.

Not only was it refreshing to meet our customers, colleagues and partners again in-person, a key focus of the event was on how to better help patients with diabetes during these changing times.

At the event, our very own registered dietitian and certified diabetes care and education specialist, Bridget Wood, shared during a Center Stage session how people living with diabetes can use the food tracker functionality within the Glooko mobile app to log their daily meals via search, voice capture and barcode scanner. The very handy food database has over 500,000 individual items, including unique regional food items from Germany, the U.K., Spain and France. Wood also highlighted how our mobile app has the capability to simultaneously add multiple lifestyle events, like medication, insulin, exercise and notes, which can be viewed alongside glucose data to reveal trends and patterns.

Along with Cecelia Health, Glooko presented a case study on how a virtual employee wellness program comprised of our digital health app for people with diabetes and virtual coaching can generate high levels of participation and improve patient outcomes.

During a Coffee Talk, Gene Arnold from Johns Hopkins Medicine and Gary Scheiner from Integrated Diabetes Services participated in a lively discussion with Glooko Chief Medical Officer Dr. Mark Clements. They discussed the clinical challenges faced when trying to educate people with diabetes without accurate data, which Glooko data visualizations to use and how clinicians are incorporating remote patient monitoring and population health management into their practices.

For those that missed it live, watch the conversation below.

MKT-0086